Trial reportThe lancet. HIV2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.
Trial report in The lancet. HIV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03497676 (Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents
Who cites it
2 citing papers in PubMed.
- Trial
- Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities.Journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
backgroundLong-acting cabotegravir and rilpivirine is the first intramuscular injectable antiretroviral treatment regimen recommended for maintenance of virological suppression in adults living with HIV-1. We report acceptability and tolerability outcomes in adolescents during 48 weeks of treatment with this regimen.
methodsIn this analysis of the phase 1/2, multicentre, open-label, non-comparative trial conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA, 144 adolescents (weight ≥35 kg) with HIV-1 were enrolled to receive long-acting intramuscular cabotegravir and rilpivirine and 140 completed 48 weeks of treatment. Participant-reported acceptability and tolerability outcomes were a Faces Scale assessment of pain at each injection, preferred treatment method, and Quality of Life Inventory (PedsQL) at baseline and across 48 weeks of treatment for participants in Botswana, South Africa, Thailand, Uganda, and the USA. USA-based participants completed a Medication Satisfaction Questionnaire (SMSQc-Teen; after week 24), assessing their satisfaction with the all-intramuscular versus their previous oral regimen. A subset of eight adolescents and three parents or caregivers in the USA underwent in-depth interviews after a minimum of 24 weeks on study. This study is registered with ClinicalTrials.gov, NCT03497676.
findingsBetween July 26, 2021, and Aug 27, 2022, 44 of 55 adolescents who participated in cohort 1 and 100 of 115 screened study-naive adolescents were enrolled in cohort 2. 70 (49%) participants were male and 74 (51%) were female. 144 adolescents completed study questionnaires; 11 adolescents and parents completed in-depth interviews. At weeks 8, 24, and 48, 138 (97%) of 142, 139 (99%) of 141, and 140 (100%) of 140 participants, respectively, preferred intramuscular injections over oral treatment. Pain was more frequent with intramuscular rilpivirine than with cabotegravir (more pain than "hurts little bit" at all timepoints: 51-62% for rilpivirine vs 12-14% for cabotegravir). Health-related quality of life was high across all timepoints (overall median 94·6 [IQR 84·8-97·8] at baseline vs 93·5 [82·6-97·8] at 48 weeks). The 19 (100%) participants who completed the SMSQc-Teen reported higher satisfaction with the all-intramuscular regimen than with previous oral regimen. In the subset of individuals who underwent in-depth interviews, a prominent theme was reduced stress between parents and adolescents with the initiation of intramuscular antiretrovirals.
interpretationAcceptability and tolerability of intramuscular cabotegravir-rilpivirine remained high through to 48 weeks of treatment, suggesting that this long-acting intramuscular treatment approach is well received by diverse populations of adolescents with HIV across multiple settings.
fundingNational Institutes of Health and ViiV Healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.